Operator of a pharmaceutical company developing inhalation treatments for severe chronic and recurrent pulmonary infections. The company is developing a drug for the treatment of Nontuberculous Mycobacteria (NTM) and Tuberculosis.
Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
---|
This information is available in the PitchBook Platform. To explore QrumPharma‘s full profile, request access.
Request a free trial